Cd3 binding antibodies

Abstract

The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.

1 .- 38 . (canceled) 
     
     
         39 . A method of treating a disease or condition in an individual in need, comprising administering an effective dose of a bispecific antibody comprising:
 a first polypeptide subunit comprising:
 a light chain variable domain (VL) comprising the sequence of SEQ ID NO: 69; and 
 a light chain constant domain (CL); 
   a second polypeptide subunit comprising:
 a heavy chain variable domain (VH) comprising: 
 (i) the sequence of SEQ ID NO: 18; or 
 (ii) the sequence of SEQ ID NO: 1; or 
 (iii) the sequence of SEQ ID NO: 6; or 
 (iv) the sequence of SEQ ID NO: 13; or 
 (v) the sequence of SEQ ID NO: 39; and 
 a heavy chain constant domain (CH) comprising a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; 
 wherein the light chain variable domain and the heavy chain variable domain together form a first binding moiety that has binding specificity for CD3; and 
   a third polypeptide subunit comprising:
 a single heavy chain variable region, in a single or tandem configuration, that has binding specificity to a protein other than CD3; and 
   a heavy chain constant domain (CH) comprising a hinge region, a CH2 domain, and a CH3 domain, in the absence of a CH1 domain.   
     
     
         40 . The method of  claim 39 , wherein the protein other than CD3 comprises a tumor-associated antigen (TAA), a tumor-specific antigen (TSA), or an immunoregulatory protein, and wherein the disease is a cancer. 
     
     
         41 . The method of  claim 39 , wherein the protein other than CD3 comprises a pathogen antigen, and wherein the disease is a pathogen infection. 
     
     
         42 . The method of  claim 39 , wherein the protein other than CD3 comprises an immunoregulatory protein, and wherein the disease is an autoimmune disease.